MAPT and Alzheimer disease: Noticeably, neurons exposed to AD BDTOs pretreated with CL3 showed decreased monomeric tau in the cytoplasmic and plasma membrane fractions as compared with untreated AD BDTOs, and no changes were observed in tau levels in the nuclear fraction (Fig. 7D).